Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA.
Neurosci Lett. 2010 Mar 26;472(3):153-6. doi: 10.1016/j.neulet.2010.01.046. Epub 2010 Feb 6.
Pioglitazone is an FDA-approved peroxisome proliferator activated receptor gamma (PPARgamma) agonist. We tested the hypothesis that treatment with pioglitazone reduces new lesion development in patients with RRMS. Twenty-two patients were treated with pioglitazone or placebo and monitored by diffusion tensor imaging (DTI) at baseline and after 12 months. A negative correlation was found between the 1-year change in relative anisotropy (RA) and fluid attenuated inversion recovery (FLAIR) lesion burden in the pioglitazone group. Regions of interest (ROIs) having high ADC and low RA values at baseline had a significantly higher chance to develop into lesions in the placebo group than similar ROIs in the pioglitazone group. These findings suggest that baseline DTI parameters can provide a prognostic surrogate marker for lesions, and that pioglitazone can reduce conversion of normal appearing white matter to lesions.
吡格列酮是一种经美国食品药品监督管理局批准的过氧化物酶体增殖物激活受体γ（PPARγ）激动剂。我们检验了以下假说，即吡格列酮治疗可减少 RRMS 患者新病灶的发展。22 名患者接受吡格列酮或安慰剂治疗，并在基线和 12 个月时通过弥散张量成像（DTI）进行监测。吡格列酮组发现相对各向异性（RA）的 1 年变化与液体衰减反转恢复（FLAIR）病变负荷之间存在负相关。基线时 ADC 值高而 RA 值低的感兴趣区域（ROI）在安慰剂组中发展为病灶的可能性明显高于吡格列酮组中类似 ROI。这些发现表明，基线 DTI 参数可提供病变的预后替代标志物，且吡格列酮可减少正常表现的白质转化为病灶。
